Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned an average rating of “Moderate Buy” from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $20.29.

Several research analysts recently commented on HIMS shares. Jefferies Financial Group increased their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their price target for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Finally, Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $695,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, COO Melissa Baird sold 17,625 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $20.51, for a total value of $361,488.75. Following the completion of the sale, the chief operating officer now directly owns 585,800 shares of the company’s stock, valued at $12,014,758. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $20.75, for a total value of $3,919,426.00. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $695,166.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 753,292 shares of company stock valued at $13,557,329. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently modified their holdings of the company. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $86,836,000. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. M&G Plc acquired a new position in Hims & Hers Health during the first quarter worth about $8,232,000. Finally, State of Michigan Retirement System boosted its stake in shares of Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Up 5.1 %

HIMS stock opened at $15.27 on Friday. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The company’s 50-day simple moving average is $17.97 and its 200-day simple moving average is $16.92. The firm has a market cap of $3.28 billion, a P/E ratio of -1,527.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same quarter last year, the business earned ($0.03) earnings per share. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. On average, analysts anticipate that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.